Navigation Links
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Date:10/6/2008

entage of patients who were free of ocular pain/discomfort, reflected by a VAS score of 0, was superior and statistically significant for the Durezol groups versus the placebo groups in both the QID and BID studies as early as Day 3/4 and throughout the study period.

Six percent of the Durezol QID patients and 3.7% of the Durezol BID patients experienced a criterion increase in intraocular pressure, defined as a pressure of greater than or equal to 21 mmHg and a change from baseline greater than or equal to 10 mmHg at the same visit, compared with 0% in both of the placebo groups.

"Durezol has shown efficacy across multiple endpoints, including pain reduction. I believe it provides a potent new treatment option with a favorable safety profile," commented Dr. Silverstein. "It is a welcome improvement to the armamentarium of ocular pharmaceuticals, particularly since ocular inflammation is common to the majority of conditions that ophthalmologists treat."

About Postoperative Inflammation

More than five million ophthalmic surgeries are performed each year in the United States. Postoperative inflammation and pain are common occurrences following these procedures and if left untreated, can interfere with a patient's visual rehabilitation or lead to further complications. Corticosteroids and non-steroidal anti-inflammatory drugs are commonly used by healthcare professionals following ophthalmic surgery.

About Durezol

Durezol (difluprednate ophthalmic emulsion) 0.05% is a topical ophthalmic corticosteroid for the treatment of inflammation and pain associated with ocular surgery. Difluprednate, the active ingredient in Durezol, is a difluorinated derivative of prednisolone and has potent anti-inflammatory activity. Prior to U.S. approval, the efficacy and safety of difluprednate in ocular inflammatory diseases had been demonstrated in an extensive preclinical and clinical program in Japan. In two U.S. Phase 3 trials evaluating Durez
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... Research and ... of the "2015 New Frontiers in ... Technologies, Competitive Landscape" report to their ... Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging ... strategic analysis of major business opportunities emerging ...
(Date:7/2/2015)... de julio de 2015 BGI anunció hoy ... alto rendimiento en Hong Kong ... Pathologists (CAP). La instalación de BGI en Hong ... de próxima generación que recibe la certificación CAP en ... estándar en prácticas de laboratorio clínico. Junto con el ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI recibe la acreditación del College of American Pathologists (CAP) 2
... 10 Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, ... the company on the pain management market.  The company plans to ... a range of products that address both the acute and chronic ... , , , ...
... Inc. (Nasdaq: YDNT ) today announced that its Board of Directors declared a ... to all shareholders of record on May 22, 2010 . , ... The Company also announced that its Board of Directors elected ... 2003 . He has assumed positions of increasing responsibility in the areas of finance, ...
Cached Medicine Technology:Xanodyne Announces Renewed Focus on Pain Management Market 2Xanodyne Announces Renewed Focus on Pain Management Market 3Xanodyne Announces Renewed Focus on Pain Management Market 4Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2
(Date:7/3/2015)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Medical Director of its Frisco facility. , “We are pleased to announce that Dr. ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Manzanares ...
(Date:7/3/2015)... ... 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... reveal biblical truth and expose popular lies regarding proper relationships according to the bible. ... immediately goes into the core of the subject by explaining why certain types of ...
(Date:7/3/2015)... , ... July 03, 2015 , ... The Celebrity Dresses ... cocktail dresses similar to those of celebrities will have the opportunity to get 10% ... checkout. This ensures that people do not have to use coupon codes or remember ...
(Date:7/2/2015)... ... ... is pleased to announce the opening of its newest location in Dallas, Texas. The opening ... yogurt chain was listed as #22 on the Inc. 500 list of fastest growing companies ... is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... 2 American Oriental,Bioengineering (NYSE: AOB ) ... a share repurchase program for the repurchase of ... stock., Purchases under this program may be ... privately negotiated transactions, and accelerated stock,repurchase transactions or ...
... Inc. (OTC,Bulletin Board: IAGX) announced today that it ... (http://www.monavie.com ) that provides for,Celadrin(R) to be ... lubricant, is a joint health breakthrough that,provides fast, ... cell membrane fluidity and elasticity.,Celadrin is a unique, ...
... low-birth-weight girls , , MONDAY, June 2 (HealthDay News) -- Children ... the risk of developing autism, new research shows. , The ... of the study, which was published in the June issue ... at the U.S. Centers for Disease Control and Prevention, helps ...
... Conn., June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ... of its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with ... (AML) had been presented at the 44th Annual Meeting ... Illinois., The Phase III trial started in March ...
... researchers at,the American Society of Hypertension (ASH), listening ... may significantly reduce high blood,pressure. This news was ... Twenty-Third,Annual Scientific Meeting and Exposition in New Orleans, ... of rhythmically homogeneous,music!, SonicMood is an Ambient ...
... , - Misys Trade Services, Including Front- ... (FTSE: MSY.L), the global application software and services,company, ... double accolade of,winning two SWIFTReady Gold labels for ... been the first trade services solutions provider to ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces US$75 Million Share Repurchase Program 2Health News:Imagenetix Enters into Business Relationship with MonaVie 2Health News:Being Born Small, Early Raises Autism Risk 2Health News:Being Born Small, Early Raises Autism Risk 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES! 2Health News:Misys Wins Prestigious Gold Labels From SWIFT for Entire Trade Services Solutions Portfolio 2
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or...
A unique system for secure fixation of the cranial bone flap after craniotomy. Craniofix eliminates the need for mini plates, screws, and additional drills....
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
Medicine Products: